Close Menu

Boehringer-Ingelheim

The final GioTag data suggests a survival benefit with the regimen among patients with EGFR-mutant NSCLC harboring acquired T790M resistance mutations.

Outcomes from the US cohort of the GioTag study confirm the benefit of Tagrisso for NSCLC patients who have become resistant to first-line Gilotrif. 

An updated analysis from the GioTag study supports the rationale for giving Gilotrif followed by Tagrisso in patients with EGFR Del19-positive lung cancer.

Keytruda and Ibrance demonstrate activity in molecularly defined populations, while a new cohort will explore Gilotrif in tumors with NRG1 fusions.

An extended labeling claim has added detection of three additional EGFR mutations to help ID NSCLC patients for whom Boehringer Ingelheim's Gilotrif is indicated.

In head-to-head studies, a next-generation EGFR inhibitor and an ALK inhibitor beat their older counterparts in staving of cancer progression.